T. Hirokazu

A phase 2 study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403).

D. Sakai, Y. Kurokawa, T. Shimokawa, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.